October 13, 2017
The delusion
The fallout from Johnson and Johnson’s (NYSE: JNJ) decision to shut down their insulin pump unit Animas continues to reverberate through the diabetes landscape. Yesterday Tandem (NASDAQ: TNDM) another insulin pump on the verge of collapsing announced they will attempt sell more shares in what likely is their last-ditch effort to stave off bankruptcy. Even if this effort is successful, and we are having a very difficult time defining just...
